Back to the Top
This might be a simple answer for people in this forum
Is there any preference for using male vs female rats when doing PK
study for anti-cancer drug (IV route of administration)?
And if yes.. why?
Thanks in advance
Bharat
Back to the Top
Hello Bharat,
well it depends upon you xenocraft model (ie breastcancer...
female .... ;-),
You will also check for which strain (Wistar, Fischer etc) the tumor
model ist established.
kind regards
Dirk
--
Dr. Dirk Scharn
Senior Scientist, DMPK
Jerini AG
Invalidenstrasse 130
10115 Berlin, Germany
eMail: scharn.at.jerini.com
Back to the Top
Hello Barth,
I agree with Dirk that your PK model should depend on the the gender
of the xenograft model. Gender differences, like different hormones,
could have an influence on the pharmacokinetic of the drug. The
earlier you are aware of this, the better.
Matthias
--
Matthias Reule PhD
29 Hoadly Road
Cambridge
CB3 0HX
UK
matthias.reule.at.googlemail.com
Back to the Top
The following message was posted to: PharmPK
Dear Bharat,
Same gender of your PD/Xenograft model will be the optimal
selection...and I have quoted two pretty old references, those may be
of some use to you....
1.Gender Differences in the Membrane Transport of Endogenous and
Exogenous Compounds; Pharmacol Rev 55:229-240, 2003
2.Gender-Based Differences in Pharmacokinetics in Laboratory Animal
Models; International Journal of Toxicology, 20:161-163, 2001
Regards,
Martin J Gnanamuthu,
Drug Metabolism and Pharmacokinetics,
Orchid Research Laboratories Ltd,
476/14, Old Mahabalipuram Road,
Sholinganallur,
Chennai-119.
|
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Pre-clinical PK and gender" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)